Your browser doesn't support javascript.
loading
Progress and Prospects of Gene Editing in Pluripotent Stem Cells.
Zhang, Zhenwu; Bao, Xinyu; Lin, Chao-Po.
Afiliação
  • Zhang Z; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Bao X; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Lin CP; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Biomedicines ; 11(8)2023 Aug 01.
Article em En | MEDLINE | ID: mdl-37626665
ABSTRACT
Applying programmable nucleases in gene editing has greatly shaped current research in basic biology and clinical translation. Gene editing in human pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), is highly relevant to clinical cell therapy and thus should be examined with particular caution. First, since all mutations in PSCs will be carried to all their progenies, off-target edits of editors will be amplified. Second, due to the hypersensitivity of PSCs to DNA damage, double-strand breaks (DSBs) made by gene editing could lead to low editing efficiency and the enrichment of cell populations with defective genomic safeguards. In this regard, DSB-independent gene editing tools, such as base editors and prime editors, are favored due to their nature to avoid these consequences. With more understanding of the microbial world, new systems, such as Cas-related nucleases, transposons, and recombinases, are also expanding the toolbox for gene editing. In this review, we discuss current applications of programmable nucleases in PSCs for gene editing, the efforts researchers have made to optimize these systems, as well as new tools that can be potentially employed for differentiation modeling and therapeutic applications.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China